agilon health delivered a clean reversal in the second quarter of fiscal 2026, with the value-based primary care operator posting $1.495 billion of revenue, $18 million of net income, and $70 million of Adjusted EBITDA for the three months ended June 30, 2026. Those numbers compare to $1.395 billion of revenue, a $104 million net loss, and an $83 million Adjusted EBITDA loss in the year-ago quarter. Medical margin, defined as medical services revenue net of the cost of medical services provided to members, swung from negative $53 million in the prior-year period to positive $197 million in the latest quarter, and management raised full-year 2026 guidance for total revenue, medical margin, and Adjusted EBITDA simultaneously. The combined print is the most decisive quarter the company has produced since its 2021 listing and is the data point that pulls the equity narrative off the "burning cash" axis and onto the "what does sustainable profitability look like" axis.
The mechanism behind the print is the same one management has been telegraphing for two quarters: a deliberate culling of unprofitable contracts, the full-year run-rate effect of last year's market exits, and a more favorable-than-expected burden of illness pattern in the first half that the company now expects to moderate. Total members on the agilon platform fell to 549,000 at quarter-end from 614,000 a year earlier, with Medicare Advantage members down 12% to 437,000. The membership drop is intentional rather than incidental and shows up in the medical margin line: per-member medical margin rose sharply, and the company generated positive earnings while operating a smaller book. We read the quarter as evidence that the platform's unit economics work when the membership is curated, which is the underlying thesis the bear case has been denying for three years.
The single load-bearing risk is whether the favorable medical cost trend that produced the $70 million of Adjusted EBITDA persists into the second half. Management's revised guidance assumes a 3% year-over-year increase in member risk scores net of the v28 model recalibration, an estimated cost trend in the low-7% range for the remainder of 2026, and approximately $25–$30 million of Adjusted EBITDA contribution from unconsolidated ACO model entities. Each of those is a reasonable estimate rather than a guarantee. The falsifiable clock is the third quarter print, due in early November 2026, where revenue is guided to $1.445–$1.475 billion, medical margin to $105–$115 million, and Adjusted EBITDA to a range straddling break-even at negative $5 million to positive $5 million. A Q3 print inside that band would confirm the trajectory; a miss of $15 million or more on Adjusted EBITDA would reopen the question of whether the second quarter was a true inflection or a one-time release of prior-year reserve true-ups.